Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters
Research record · 2023
- What was studied
- Molecular transport feasibility investigation
- Main finding
- Examines transporter interactions for 26 ultrashort peptides. Feasibility at this level is not demonstrated oral bioavailability, brain delivery or clinical efficacy.
Study data at a glance
- Participants or experimental model
- Molecular transport feasibility investigation
- Reported results
- Examines transporter interactions for 26 ultrashort peptides. Feasibility at this level is not demonstrated oral bioavailability, brain delivery or clinical efficacy.
Study limitations and source details
Study limitations
- Source-linked does not mean a completed risk-of-bias review.
- A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.
Source details
Title, authors and abstract checked; detailed experimental/computational methods await appraisal.
Sources checked
Citation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
V. Kh. Khavinson, N. S. Linkova, A. I. Rudskoy, M. G. Petukhov. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters Original article; author-hosted PDF
Related compounds
Pinealon
A synthetic tripeptide, Glu–Asp–Arg (EDR). Researchers have examined its effects in neuronal aging models and measured functional outcomes in human performance studies.
Epitalon
A synthetic tetrapeptide, Ala–Glu–Asp–Gly (AEDG, also called Epithalon), developed from pineal-gland research. Human studies examined melatonin secretion, circadian markers and retinal function.